Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 Posoleucel (ALVR105,Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant

NCT05305040 is registered in ClinicalTrials.gov with AlloVir as lead sponsor.

NCT NCT05305040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05305040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 Posoleucel (ALVR105,Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
Lead sponsor
AlloVir
Phase
Phase 2/3
Overall status
Terminated
Start date
March 24, 2022
Completion date
January 30, 2024
Enrollment
451 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

adenovirus infection, bk virus infection, cytomegalovirus infections, epstein-barr virus infections, human herpes virus-6 infection, jc virus infection